Topical Diclofenac Unnecessary Post-Photorefractive Keratectomy

This article originally appeared here.
Share this content:
Topical Diclofenac Unnecessary Post-Photorefractive Keratectomy
Topical Diclofenac Unnecessary Post-Photorefractive Keratectomy

FRIDAY, Jan. 9, 2015 (HealthDay News) -- For patients undergoing photorefractive keratectomy surgery, the administration of postoperative topical diclofenac does not alleviate pain, but is effective for local signs such as eyelid edema, according to a study published in the December issue of Clinical & Experimental Ophthalmology.

Alireza Eslampoor, M.D., from the Tehran University of Medical Sciences in Iran, and colleagues conducted a prospective randomized trial involving 68 individuals undergoing bilateral photorefractive keratectomy for myopic correction with or without astigmatism. Participants received 100 mg of extended-release oral diclofenac twice before surgery. After surgery, patients were randomized into case (diclofenac 0.1 percent drop administered for three days postoperatively) and control (given artificial tears) groups.

The researchers observed no significant between-group difference in pain level at two days after surgery. Furthermore, neither photophobia nor functional activity differed between the groups. In the control group, eyelid edema and conjunctival injection levels were significantly higher (P < 0.001).

"Administration of topical diclofenac to a standardized postoperative pain regime did not alleviate post-photorefractive keratectomy pain, although it is effective in local signs like eyelid edema and conjunctival injection," the authors write. "It can be concluded that oral diclofenac is sufficient in the management of post-photorefractive keratectomy pain and addition of the topical diclofenac is unnecessary."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »